Aria Dibiase, MD
Advanced Heart Failure and Transplant Cardiology · Palo Alto, CANPI 1033273727
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,000 of the $3,685 with a category attached, or 81.4%. Biotronik Inc. accounts for 86.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $3,213 and has fallen 96.0% since, to $129 in 2024. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in CA, where the typical reported total is $9,367.
Across 6 payments — averaging $614.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$3K
- Edwards Lifesciences$202
- Abbott$142
- Impulse Dynamics (USA) Inc.$129
- Amgen$13
What the payments were for
- Speaking & faculty fees$3,00081%
- Travel & lodging$1995%
- Food & beverage$48613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 2 | $3,199 |
| Edwards Lifesciences | 1 | $202 |
| Abbott | 1 | $142 |
| Impulse Dynamics (USA) Inc. | 1 | $129 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$258
- Mitra Clip system$142
How this compares
$3,685 in reported general payments places this provider in the 40th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 36 | $807,764 |
| VyndaqelTafamidis Meglumine | 13 | $469,142 |
| EliquisApixaban | 113 | $140,999 |
| EntrestoSacubitril/Valsartan | 125 | $119,391 |
| FarxigaDapagliflozin Propanediol | 32 | $34,351 |
| JardianceEmpagliflozin | 22 | $33,182 |
| XareltoRivaroxaban | 14 | $22,152 |
| Metoprolol Succinate | 322 | $4,713 |
| Atorvastatin Calcium | 275 | $2,736 |
| Rosuvastatin Calcium | 124 | $2,143 |
| Irbesartan | 129 | $1,951 |
| Carvedilol | 150 | $1,601 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 39 | $1,514 |
| Spironolactone | 89 | $1,103 |
| Valsartan | 38 | $1,089 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Palo Alto
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Rajeev Mohanla Jolla$357K
- Marcus UreySan Diego$341K
- Munir JanmohamedSacramento$314K
- Barry GreenbergSan Diego$270K
- Ronald WittelesStanford$251K
- Gurpreet SodhiSacramento$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.